Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Abstract Neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system. The potential of numerous antidiabetic agents to m...
Saved in:
Main Authors: | Chien-Tai Hong, Jia-Hung Chen, Chaur-Jong Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-11-01
|
Series: | Journal of Biomedical Science |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12929-024-01090-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01) -
Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01) -
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Hayeon Kim, et al.
Published: (2024-10-01) -
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Tian-Yi Ren, et al.
Published: (2024-10-01) -
One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)